No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Drug Manufacturers - Specialty & Generic
AstraZeneca Pharma India Limited operates as a biopharmaceutical entity, engaged in the development, production, and global commercialization of pharmaceutical products, serving both the Indian domestic market and international clientele. The company offers an extensive range of medications, including treatments for cardiovascular conditions and diabetes, marketed under brands such as Brilinta, Betaloc, Crestor, Forxiga, Imdur, Kombiglyze XR, Onglyza, Seloken XL, Xigduo XR, and QTERN. Its respiratory portfolio features products like Symbicort and FASENRA, while its oncology division provides various cancer therapies, including LYNPARZA, Tagrisso, Iressa, Calquence, Casodex, Faslodex, Zoladex, and Arimidex. Furthermore, the firm extends its product line to encompass therapeutic solutions for renal, metabolic, and immunological disorders. Beyond its pharmaceutical offerings, AstraZeneca Pharma India Limited also provides clinical trial services. Established in 1979, the company is based in Bengaluru, India, and functions as a subsidiary of AstraZeneca Pharmaceuticals AB.
www.astrazeneca.inNo one on the platform currently holds ASTRAZEN.NS.
No tracked institution reports a position in ASTRAZEN.NS as of their last filing.
No one on the platform has traded ASTRAZEN.NS yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 32.5% | 67.7% | 49.8% | — | — | — |
| Rev. Growth % | 32.8% | 23.0% | ||||
| Profit Margin % | 8.2% | 9.0% | 8.1% | |||
| Free Cash Flow Margin % | 0.1% | 4.3% | 5.4% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2027 | $8.4B | -30.6% | $33.34 | $33.34–$33.34 | — | 1 |
| 2028 | $8.4B | +0.0% | $33.34 | $33.34–$33.34 | — | 1 |
| 2029 | $9.1B | +8.1% | $32.31 | $32.31–$32.31 | — | 1 |
| 2030 | $10.1B | +11.0% | $36.51 | $36.51–$36.51 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 7 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-05-28 | $5.16 | $17.95 | +247.9% |
| 2026-02-09 | $8.29 | $13.04 | +57.3% |
| 2025-11-11 | $8.29 | $21.69 | +161.6% |
| 2025-08-14 | $8.29 | $22.33 | +169.4% |
| 2025-05-30 | $5.16 | $23.30 | +351.6% |
| 2025-02-11 | $8.29 | $12.34 | +48.9% |
| 2024-11-13 | $5.16 | $15.37 | +197.9% |
| 2024-08-08 | $8.29 |
| Symbol | Price | Today | Mkt cap | P/E |
|---|---|---|---|---|
| ASTRAZEN.NSAstraZeneca Pharma India Limited | $6695.50 | -1.02% | $167.4B | — |
| ERIS.BOEris Lifesciences Limited | $1311.00 | -3.25% | $181.7B | — |
| ERIS.NSEris Lifesciences Limited | $1310.10 | -3.35% | $181.6B | — |
| JBCHEPHARM.BOJ. B. Chemicals & Pharmaceuticals Limited | $2412.25 | -3.70% | $387.3B | — |
| JBCHEPHARM.NSJ. B. Chemicals & Pharmaceuticals Limited |
| $-4.72 |
| -156.9% |
| $2416.10 |
| +0.30% |
| $387.9B |
| — |
| NEULANDLAB.BONeuland Laboratories Limited | $22522.85 | -3.87% | $289.5B | — |
| NEULANDLAB.NSNeuland Laboratories Limited | $22595.00 | -3.99% | $289.9B | — |
Source: Financial Modeling Prep · peers by sector/industry